Tragara Pharmaceuticals' Apricoxib Reverses EMT, a Key Process for Cancer Progression and ... ( SAN DIEGO May 26 2011 /- Tragara Phar...)

Tragara Pharmaceuticals' Apricoxib Reverses EMT, a Key Process for Cancer Progression and Metastasis

Date:5/26/2011

SAN DIEGO, May 26, 2011 /PRNewswire/ -- Tragara Pharmaceuticals, Inc. announced today that apricoxib (Capoxigem®, TG01), its novel COX-2 inhibitor in development for select cancer types, demonstrated reversal of the epithelial-mesenchymal transition (EMT) in xenograft models of several types of solid tumors. These data results were presented at the 2011 American Society for Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium and the 2011 American Association for Cancer Research (AACR) Annual Meeting and demonstrate that apricoxib potently inhibits the activity of COX-2 and COX-2 derived prostaglandin E2 (PGE2), which in turn mediates EMT and the associated progression and metastasis of solid tumors.

"Reversal of EMT may provide several clinical benefits to patients with non-small cell lung cancer and pancreatic cancer," stated Sara Zaknoen, M.D., chief medical officer, Tragara Pharmaceuticals, Inc. "Patients may experience longer survival due to effects of EMT reversal on metastases and the cancer stem cell, and benefit from the reversal of resistance to drugs such as erlotinib."

Tragara has completed two phase II clinical trials of apricoxib. Results from the APRiCOT-L trial, a biomarker-based, phase II, randomized, placebo-controlled study of apricoxib in combination with erlotinib in non-small cell lung cancer, will be presented on June 6th at the ASCO meeting in Chicago. A second phase II study of apricoxib in combination with gemcitabine and erlotinib has completed enrollment and is currently being analyzed.

"COX-2 has been implicated in EMT, so we were gratified to see robust reversal of EMT resulting from apricoxib treatment in xenograft models of pancreatic, colon, and head and neck cancers," stated Francis Burrows, Ph.D., head of oncology biology, Tragara Pharmaceuticals, Inc. "This effect was associated with profound inhibition of metastasis in orthotopic cancer models but, interestingly, apricoxib-mediated EMT re
'/>"/>

SOURCE Tragara Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate

Post Your Comments:

(Date:5/20/2013)... -- Life Technologies Corporation (NASDAQ: LIFE ... and 3500xL Dx Genetic Analyzers have been approved by ... Mexico for diagnostic use. The ... to serve the clinical end market in ... -based solutions. The Applied Biosystems™ 3500 ...

(Date:5/20/2013)... , May 20, 2013 Hyland ... healthcare industry by creating the Multi-Disciplinary Clinical Leadership ... variety of medical experts with diverse healthcare experience, ... healthcare industry to create new software solutions that ... specific needs of patients and staff. ...

(Date:5/20/2013)... May 20, 2013 Enrollment of patients with ... 2b dose-finding clinical trial of product candidate NewMet ... treatment for Type 2 diabetes. Elcelyx expects to complete ... in June. Results of the trial,s primary endpoint of ... summer, and the read-out for long-term glucose lowering and ...

Breaking Medicine Technology:Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico 2 Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico 3 Hyland Software Forms Multi-Disciplinary Clinical Leadership Team to Augment Healthcare Solutions 2 Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2 Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3 Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4

[0] Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico [0] Hyland Software Forms Multi-Disciplinary Clinical Leadership Team to Augment Healthcare Solutions [0] Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes

... Nov. 1, 2011 Champions Oncology, Inc. ... CSBR ) , a company engaged in the development ... development and use of oncology drugs, has appointed Gary ... Vice President and Chief Financial Officer. Joel Ackerman, the ...

... 1, 2011 Trend Micro Incorporated (TYO: 4704; TSE: ... commitment to the security of the nation,s critical healthcare ... Innovation, Safety and Security Consortium (MDISS). As ... Consortium in helping to protect public health and well-being ...

Cached Medicine Technology:Champions Oncology, Inc. Appoints Executive Vice President and Chief Financial Officer to Management Team and Corporate Office Relocation 2 Champions Oncology, Inc. Appoints Executive Vice President and Chief Financial Officer to Management Team and Corporate Office Relocation 3 Trend Micro Joins Industry Leaders in the Effort to Secure Critical IT Healthcare Infrastructure 2 Trend Micro Joins Industry Leaders in the Effort to Secure Critical IT Healthcare Infrastructure 3

Champions Oncology, Inc. Appoints Executive Vice President and Chief Financial Officer to Management Team and Corporate Office Relocation Trend Micro Joins Industry Leaders in the Effort to Secure Critical IT Healthcare Infrastructure

(Date:5/21/2013)... It took Willie Benitez, a heroin ... sixth time on a fifteen year sentence, six months ... to trust him enough to allow Willie to start ... “NarcoNon” Willie intended to name his “drug rehabilitation foundation,” ... and did start up that class. , Early ...

(Date:5/21/2013)... Leading New Jersey real estate agent, ... One of her favorite aspects of walkable places is ... light of the current childhood obesity epidemic that plagues ... walkable living. , A New York Academy of Sciences ... neighborhoods as a key combatant to obesity. The same ...

(Date:5/21/2013)... 2013 Dr. James C. Wittig, Chief ... the Sarcoma Division of the John Theurer Cancer Center ... been named one of the top 13 Orthopedic Oncologists ... Dr. Wittig is one of approximately 125 surgeons in ... created by surveying thought leaders in the field of ...

(Date:5/21/2013)... The Michigan Lupus Foundation will be holding a ... 11th. , Meeting Details: , Tuesday, June 11th , ... Room 5 (Lower Level), 1375 North Main Street, Lapeer, ... people with lupus and their family and friends to ... better understanding of this disease and how to fight ...

(Date:5/21/2013)... 21, 2013 Joe Vitale, a positive thinking ... adapter of the Fisker electric car. After a year and ... the car company went bankrupt, the bestselling author turned grumpy ... , "It's a gas guzzler's anthem," says Vitale, 59, who ... "Sun Will Rise." , Owning this Fisker was a ...

Breaking Medicine News(10 mins):Health News:Narconon Releases Report on its Very First Narconon Program, the First of 23 Reviews or Evaluations of Results up to 2009 2 Health News:Narconon Releases Report on its Very First Narconon Program, the First of 23 Reviews or Evaluations of Results up to 2009 3 Health News:Narconon Releases Report on its Very First Narconon Program, the First of 23 Reviews or Evaluations of Results up to 2009 4 Health News:Narconon Releases Report on its Very First Narconon Program, the First of 23 Reviews or Evaluations of Results up to 2009 5 Health News:New Jersey Realtor, Lina Panza, Advocates Walkable Neighborhoods to Combat Childhood Obesity 2 Health News:New Jersey Realtor, Lina Panza, Advocates Walkable Neighborhoods to Combat Childhood Obesity 3 Health News:James C. Wittig, MD, Selected as one of America's Top 13 Orthopaedic Oncologists 2 Health News:James C. Wittig, MD, Selected as one of America's Top 13 Orthopaedic Oncologists 3 Health News:Upset Fisker Owner Records Gas Guzzler Anthem 2

[0] Narconon Releases Report on its Very First Narconon Program, the First of 23 Reviews or Evaluations of Results up to 2009 [0] New Jersey Realtor, Lina Panza, Advocates Walkable Neighborhoods to Combat Childhood Obesity [0] James C. Wittig, MD, Selected as one of America's Top 13 Orthopaedic Oncologists [0] Lupus Support Group Meeting in Lapeer on June 11th [0] Upset Fisker Owner Records Gas Guzzler Anthem

... someday help control anxiety, experts say, , , FRIDAY, May 15 ... anxiety isn,t something associated with heights, a job interview or ... state of worry and tension that affects twice as many ... slowly eroding their quality of life. , But a new ...

... ORLANDO A pill used for nerve pain offers women ... 45th Annual Meeting of the American Society of Clinical ... hot flash severity and frequency about 20 percent more than ... the same benefit as gabapentin, an older, related drug, as ...

... in GI and Endoscopy Nursing at SGNA 36th Annual ... Nurses and Associates, Inc. (SGNA) is proud to honor ... awards that recognize their dedication to the field and ... distinguished awards represent the best in GI and endoscopy ...

... Palatin Technologies, Inc. (NYSE Amex: PTN ) announced ... Palatin reported net income of $0.1 million, or $0.00 per basic ... to a net loss of $5.1 million, or $0.06 per basic ... revenues in the quarter ended March 31, 2009 were $5.2 million, ...

... 15 /PRNewswire-Asia-FirstCall/ -- Shengtai,Pharmaceutical, Inc. (OTC Bulletin Board: ... distributor of high-quality, pharmaceutical grade,glucose products in China, ... of fiscal 2009 ended March 31, 2009. , ... has impacted our operations thus far in,fiscal year ...

... Dr. Bruno E. Gerber is recognized in ... is a Consultant Orthopedic Surgeon with a special ... of the lower limbs. He also is employed ... development project regarding innovative orthopedic laser treatment.Dr. Gerber ...

Fear Response May Stem From Protein in Brain Mayo Clinic researchers say agent provides treatment option for women with hot flashes SGNA Honors Outstanding Gastroenterology and Endoscopy Professionals With Nationwide Awards Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results Continental Who's Who Executive Press Release: Dr. Bruno E. Gerber - Medical Professional

... The TOPCON OM-4 Ophthalmometer ... compactly designed and easy ... providing precise objective measurements ... of curvature plus accurate ...

... Based on the latest digital chip ... FA/Color System from Topcon features 3,072 x ... range for each color channel! The system ... also features real-time image acquisition, which facilitates ...

... Set offers a maximum selection ... corrected curve additive design that ... spacing between combined lenses. This ... be read directly from the ...

... power table has everything that you need ... new AIT-15 offers 20 mm of additional ... and locking castors to secure the table. ... for most any application. Use a double ...

Medicine Products:

Topcon OM-4 Ophthalmometer Topcon IMAGEnet 2000 FA/Color System with 3,072 x 2,048 pixels Topcon TLS-FD trial lens set AIT-15 instrument table